deltatrials
Completed PHASE2 NCT02008084

A Pilot Study to Evaluate the Lipid Effects of TRIA-662

A Randomized, Double-blind, Placebo-controlled, Forced Dose-escalation, Multi-center Pilot Study to Evaluate the Lipid Regulating Effects of TRIA-662 (1-methylnicotinamide Chloride)

Sponsor: Cortria Corporation

Conditions Hypertriglyceridemia Mixed Hyperlipidemia
Interventions Placebo TRIA-662
Updated 6 times since 2017 Last updated: Jan 26, 2016 Started: Dec 31, 2013 Primary completion: Oct 31, 2015 Completion: Oct 31, 2015

A PHASE2 clinical study on Hypertriglyceridemia and Mixed Hyperlipidemia, this trial is completed. The trial is conducted by Cortria Corporation and has accumulated 6 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cortria Corporation
  • Montreal Heart Institute
Data source: Cortria Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Calgary, Canada, Cornwall, Canada, Drummondville, Canada, Edmonton, Canada, Kitchener, Canada, London, Canada, Longueuil, Canada, Moncton, Canada, Montreal, Canada, Mount Pearl, Canada and 6 more location s